Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Novel Therapies for Metabolic Complications of Lipodystrophies

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2013 by Abhimanyu Garg, University of Texas Southwestern Medical Center.
Recruitment status was:  Recruiting
National Institutes of Health (NIH)
Amylin Pharmaceuticals, LLC.
Information provided by (Responsible Party):
Abhimanyu Garg, University of Texas Southwestern Medical Center Identifier:
First received: April 4, 2007
Last updated: June 19, 2013
Last verified: June 2013
Lipodystrophies represent a therapeutic challenge with regards to the management of the diabetes, insulin resistance, hypertriglyceridemia and fatty liver which frequently present in conjunction with significant adipose tissue loss. The purpose of the study and it's four subprojects is to examine the safety and efficacy of various novel interventions designed to improve or resolve the fatty liver, hypertriglyceridemia, and insulin resistance or diabetes that is seen in these patients.

Condition Intervention Phase
Insulin Resistance
Hepatic Steatosis
Other: low-fat diet ( Still recruiting )
Other: Diet
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Novel Therapies for Metabolic Complications in Patients With Lipodystrophies

Resource links provided by NLM:

Further study details as provided by Abhimanyu Garg, University of Texas Southwestern Medical Center:

Primary Outcome Measures:
  • Project specific: improvement in serum triglycerides, insulin resistance, liver triglyceride content, liver volume, Hgb A1c, [ Time Frame: 6 to 12 months ]

Estimated Enrollment: 72
Study Start Date: April 2006
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Low fat diet is the "drug"
Diet 10% fat versus 35% fat
Other: low-fat diet ( Still recruiting )
This study will compare 10% fat versus 35% fat diets in terms if effect on liver fat, triglycerides adn other metabolic parameters.
Other Name: Low fat versus extremely low fat Diet
Other: Diet
10 % versus 35 % fat in diet

Detailed Description:

We propose novel therapeutic approaches for the management of metabolic complications in patients with lipodystrophies. The four interventions to be tested are:

Hypothesis 1: An extremely low fat diet. Hypothesis 2: Leptin replacement therapy. Hypothesis 3: Cholic acid therapy.. Hypothesis 4: Peroxisome proliferator activated receptors (PPAR) agonist, pioglitazone.


Ages Eligible for Study:   14 Years to 70 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

General Inclusion criteria:

  • Patients with lipodystrophies as diagnosed by clinical criteria
  • Any one of the following:

    • Diabetes mellitus, or
    • Fasting serum triglycerides greater than 200 mg/dL, or
    • Fasting serum insulin greater than 30 U/mL, or
    • Hepatic steatosis ( greater than 5.6% hepatic triglyceride content) as demonstrated by 1H MRS.

Exclusion Criteria:

  • Known liver disease due to causes other than non-alcoholic steatohepatitis:
  • Current alcohol abuse (more than 7 drinks or 210 g per wk for women and more than 14 drinks or 420 g per wk for men).
  • Positive serological markers of hepatitis B and C.
  • Autoimmune hepatitis, autoimmune cholestatic liver disorders, Wilson disease and Alpha-1-antitrypsin deficiency as indicated by clinical and laboratory tests.
  • Drug-induced liver disease
  • Evidence of hepatocellular carcinoma: alpha-fetoprotein levels greater than 200 ng/ml and/or liver mass on imaging study suggestive of liver cancer.
  • Decompensated liver disease as evidenced by clinical features of hepatic failure (variceal bleeding, ascites, hepatic encephalopathy etc.) and laboratory investigations (prolonged prothrombin time, hypoalbuminemia, presence of esophageal varices etc.)
  • Use of the drugs which can potentially decrease hepatic steatosis during previous 3 months; high-dose vitamin E, betaine, acetylcysteine, choline and probucol.
  • Significant systemic or major illnesses other than liver disease (congestive heart failure, unstable angina, cerebrovascular disease, respiratory failure, renal failure [serum creatinine more then 2 mg/dL], acute pancreatitis, organ transplantation, serious psychiatric disease, and malignancy) that could interfere with the trial and adequate follow up.
  • Acute medical illnesses precluding participation in the studies.
  • Known HIV infected patient.
  • Current substance abuse.
  • Pregnant or lactating women.
  • Hematocrit of less than 30%.
  • History of weight loss ( more than 10%) or use of weight loss drugs such as sibutramine or orlistat in the last 3 months.

Each subproject has additional specific inclusion and exclusion criteria

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00457938

Contact: Claudia Quittner, RN, BSN, MS 214-648-9296
Contact: Zahid Ahmad, MD 214-648-2377

United States, Texas
UT Southwestern Medical Center Recruiting
Dallas, Texas, United States, 75390
Contact: Claudia Quittner, RN, BSN, MS    214-648-9296   
Contact: Zahid Ahmad, M.D.    214-648-2377   
Principal Investigator: Abhimanyu Garg, M.D.         
Sub-Investigator: Zahid Ahmad, M.D.         
Sponsors and Collaborators
University of Texas Southwestern Medical Center
National Institutes of Health (NIH)
Amylin Pharmaceuticals, LLC.
Principal Investigator: Abhimanyu Garg, MD UT Southwestern Medical Center
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Abhimanyu Garg, Chairman, Division Nutrition and Metabolic Diseases, Professor Internal Medicine, University of Texas Southwestern Medical Center Identifier: NCT00457938     History of Changes
Other Study ID Numbers: RO1-074959
Study First Received: April 4, 2007
Last Updated: June 19, 2013

Keywords provided by Abhimanyu Garg, University of Texas Southwestern Medical Center:

Additional relevant MeSH terms:
Insulin Resistance
Fatty Liver
Glucose Metabolism Disorders
Metabolic Diseases
Lipid Metabolism Disorders
Skin Diseases, Metabolic
Skin Diseases
Liver Diseases
Digestive System Diseases processed this record on May 25, 2017